The Biotech Growth Trust PLC
The Biotech Growth Trust PLC is a closed ended equity mutual fund launched by Frostrow Capital LLP. It is co-managed by OrbiMed Capital LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the biotechnology sector. The fund invests in stocks of companies across all market capitalizations. It employs fundamental analysis to create … Read more
The Biotech Growth Trust PLC (BIOG) - Net Assets
Latest net assets as of September 2025: GBX257.88 Million GBX
Based on the latest financial reports, The Biotech Growth Trust PLC (BIOG) has net assets worth GBX257.88 Million GBX as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX289.97 Million) and total liabilities (GBX32.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX257.88 Million |
| % of Total Assets | 88.93% |
| Annual Growth Rate | 9.39% |
| 5-Year Change | -63.22% |
| 10-Year Change | -41.57% |
| Growth Volatility | 38.11 |
The Biotech Growth Trust PLC - Net Assets Trend (2004–2025)
This chart illustrates how The Biotech Growth Trust PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for The Biotech Growth Trust PLC (2004–2025)
The table below shows the annual net assets of The Biotech Growth Trust PLC from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | GBX221.21 Million | -38.78% |
| 2024-03-31 | GBX361.31 Million | +9.39% |
| 2023-03-31 | GBX330.29 Million | -16.21% |
| 2022-03-31 | GBX394.21 Million | -34.46% |
| 2021-03-31 | GBX601.47 Million | +64.53% |
| 2020-03-31 | GBX365.57 Million | -10.59% |
| 2019-03-31 | GBX408.88 Million | -2.04% |
| 2018-03-31 | GBX417.40 Million | -6.92% |
| 2017-03-31 | GBX448.41 Million | +18.45% |
| 2016-03-31 | GBX378.57 Million | -29.01% |
| 2015-03-31 | GBX533.30 Million | +56.74% |
| 2014-03-31 | GBX340.25 Million | +39.19% |
| 2013-03-31 | GBX244.44 Million | +56.56% |
| 2012-03-31 | GBX156.13 Million | +29.23% |
| 2011-03-31 | GBX120.82 Million | +0.33% |
| 2010-03-31 | GBX120.42 Million | +71.51% |
| 2009-03-31 | GBX70.21 Million | +8.85% |
| 2008-03-31 | GBX64.50 Million | -16.02% |
| 2007-03-31 | GBX76.80 Million | +110.10% |
| 2006-03-31 | GBX36.56 Million | +20.06% |
| 2005-03-31 | GBX30.45 Million | -9.42% |
| 2004-03-31 | GBX33.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to The Biotech Growth Trust PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX6.78 Million | 3.06% |
| Other Components | GBX214.43 Million | 96.94% |
| Total Equity | GBX221.21 Million | 100.00% |
The Biotech Growth Trust PLC Competitors by Market Cap
The table below lists competitors of The Biotech Growth Trust PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CBEE1
SA:CBEE1
|
$1.38K |
|
Egyptian Transport (EGYTRANS)
EGX:ETRS
|
$1.39K |
|
MM Group For Industry And International Trade
EGX:MTIE
|
$1.39K |
|
Shahzad Textile Mills Limited
KAR:SZTM
|
$1.39K |
|
Hayleys Fabric PLC
CM:MGTN0000
|
$1.38K |
|
Suez Cement
EGX:SUCE
|
$1.38K |
|
Nodechain Inc
PINK:NODC
|
$1.38K |
|
SAMEER AFRICA LTD
XNAI:SAMEER
|
$1.38K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in The Biotech Growth Trust PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 361,307,000 to 221,206,000, a change of -140,101,000 (-38.8%).
- Net loss of 82,661,000 reduced equity.
- Share repurchases of 54,483,000 reduced equity.
- Other comprehensive income decreased equity by 250,417,000.
- Other factors increased equity by 247,460,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-82.66 Million | -37.37% |
| Share Repurchases | GBX54.48 Million | -24.63% |
| Other Comprehensive Income | GBX-250.42 Million | -113.21% |
| Other Changes | GBX247.46 Million | +111.87% |
| Total Change | GBX- | -38.78% |
Book Value vs Market Value Analysis
This analysis compares The Biotech Growth Trust PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 175.94x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1105.79x to 175.94x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | GBX1.12 | GBX1235.00 | x |
| 2005-03-31 | GBX1.01 | GBX1235.00 | x |
| 2006-03-31 | GBX1.33 | GBX1235.00 | x |
| 2007-03-31 | GBX1.29 | GBX1235.00 | x |
| 2008-03-31 | GBX1.00 | GBX1235.00 | x |
| 2009-03-31 | GBX1.25 | GBX1235.00 | x |
| 2010-03-31 | GBX2.17 | GBX1235.00 | x |
| 2011-03-31 | GBX1.84 | GBX1235.00 | x |
| 2012-03-31 | GBX2.45 | GBX1235.00 | x |
| 2013-03-31 | GBX3.81 | GBX1235.00 | x |
| 2014-03-31 | GBX5.00 | GBX1235.00 | x |
| 2015-03-31 | GBX8.16 | GBX1235.00 | x |
| 2016-03-31 | GBX6.11 | GBX1235.00 | x |
| 2017-03-31 | GBX7.80 | GBX1235.00 | x |
| 2018-03-31 | GBX7.47 | GBX1235.00 | x |
| 2019-03-31 | GBX7.51 | GBX1235.00 | x |
| 2020-03-31 | GBX8.10 | GBX1235.00 | x |
| 2021-03-31 | GBX15.02 | GBX1235.00 | x |
| 2022-03-31 | GBX9.51 | GBX1235.00 | x |
| 2023-03-31 | GBX8.20 | GBX1235.00 | x |
| 2024-03-31 | GBX10.02 | GBX1235.00 | x |
| 2025-03-31 | GBX7.02 | GBX1235.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently The Biotech Growth Trust PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: -0.34x
- • Equity Multiplier: 1.02x
- Recent ROE (-37.37%) is below the historical average (7.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 41.69% | 93.64% | 0.44x | 1.01x | GBX10.65 Million |
| 2005 | -10.06% | 0.00% | -0.07x | 1.01x | GBX-6.11 Million |
| 2006 | 22.66% | 85.60% | 0.25x | 1.07x | GBX4.63 Million |
| 2007 | 0.91% | 22.29% | 0.04x | 1.05x | GBX-6.98 Million |
| 2008 | -13.84% | 0.00% | -0.14x | 1.03x | GBX-15.38 Million |
| 2009 | 25.60% | 92.93% | 0.26x | 1.06x | GBX10.96 Million |
| 2010 | 23.82% | 94.10% | 0.23x | 1.10x | GBX16.65 Million |
| 2011 | 1.66% | 63.25% | 0.02x | 1.12x | GBX-10.08 Million |
| 2012 | 25.95% | 91.71% | 0.27x | 1.04x | GBX24.91 Million |
| 2013 | 31.78% | 99.19% | 0.29x | 1.11x | GBX52.19 Million |
| 2014 | 25.37% | 98.90% | 0.23x | 1.12x | GBX52.31 Million |
| 2015 | 40.18% | 99.60% | 0.37x | 1.10x | GBX160.93 Million |
| 2016 | -34.06% | 0.00% | -0.30x | 1.12x | GBX-166.81 Million |
| 2017 | 21.98% | 97.84% | 0.22x | 1.03x | GBX53.58 Million |
| 2018 | -7.13% | 0.00% | -0.06x | 1.07x | GBX-71.52 Million |
| 2019 | 5.16% | 91.56% | 0.05x | 1.05x | GBX-19.79 Million |
| 2020 | 16.66% | 95.32% | 0.16x | 1.10x | GBX24.34 Million |
| 2021 | 33.32% | 98.08% | 0.31x | 1.08x | GBX140.28 Million |
| 2022 | -51.35% | 0.00% | -0.49x | 1.08x | GBX-241.84 Million |
| 2023 | -12.50% | 0.00% | -0.10x | 1.09x | GBX-74.33 Million |
| 2024 | 20.65% | 92.85% | 0.20x | 1.14x | GBX38.47 Million |
| 2025 | -37.37% | 0.00% | -0.34x | 1.02x | GBX-104.78 Million |
Industry Comparison
This section compares The Biotech Growth Trust PLC's net assets metrics with peer companies in the Asset Management industry.
Industry Context
- Industry: Asset Management
- Average net assets among peers: $395,694,700
- Average return on equity (ROE) among peers: -81.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| The Biotech Growth Trust PLC (BIOG) | GBX257.88 Million | 41.69% | 0.12x | $1.38K |
| 3I Infrastructure PLC (3IN) | $1.09 Billion | 8.57% | 0.18x | $396.99K |
| 450 PLC (450) | $1.30 Million | -791.13% | 5.03x | $1.71K |
| abrdn Asian Income Fund Limited (AAIF) | $431.48 Million | 11.10% | 0.09x | $315.37 |
| Abrdn Asia Focus PLC (AAS) | $464.40 Million | -2.37% | 0.15x | $434.78 |
| Albion Technology & General VCT PLC (AATG) | $34.46 Million | 4.41% | 0.01x | $78.71 |
| Aberdeen Diversified Income and Growth Trust PLC (ADIG) | $492.42 Million | 0.00% | 0.32x | $16.61 |
| Aquila Energy Efficiency Trust PLC (AEET) | $97.38 Million | -0.64% | 0.00x | $2.38K |
| Aquila European Renewables Income PLC (AERI) | $320.23 Million | -9.29% | 0.00x | $2.45K |
| Artemis UK Future Leaders plc (AFL) | $84.35 Million | -40.52% | 0.02x | $401.26 |
| AVI Global Trust PLC (AGT) | $938.94 Million | 2.59% | 0.12x | $2.83 Million |